RMC-9805

News alerts, weekly reports and conference planners

Company:

Revolution Medicines

Drug class:

KRAS G12D inhibitor

Related drugs:

‹

›

KRAS G12D	Pancreatic Ductal Adenocarcinoma	KRAS G12D	Pancreatic Ductal Adenocarcinoma	RMC-9805 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) RMC-9805 Sensitive : D AACR 2023 - 1wk	RMC-9805 Sensitive: D – Preclinical AACR 2023 - 1 week RMC-9805 Sensitive : D AACR 2023 - 1 week - (New D)
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	RMC-9805 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) RMC-9805 Sensitive : D AACR 2023 - 1wk	RMC-9805 Sensitive: D – Preclinical AACR 2023 - 1 week RMC-9805 Sensitive : D AACR 2023 - 1 week - (New D)

Associations
(2)